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Primary immunodeficiency disorders (PIDs) render patients vulnerable to infection 
with a wide range of microorganisms and thus provide good in vivo models for the 
assessment of immune responses during infectious challenges. Priming of the immune 
system, especially in infancy, depends on different environmental exposures and med-
ical practices. This may determine the timing and phenotype of clinical appearance 
of immune deficits as exemplified with early exposure to Bacillus Calmette-Guérin 
(BCG) vaccination and dissemination in combined immunodeficiencies. Varied phe-
notype expression poses a challenge to identification of the putative immune deficit. 
Without the availability of genomic diagnosis and data analysis resources and with 
limited capacity for functional definition of immune pathways, it is difficult to establish 
a definitive diagnosis and to decide on appropriate treatment. This study describes 
the use of exome sequencing to identify a homozygous recessive variant in MAP3K14, 
NIKVal345Met, in a patient with combined immunodeficiency, disseminated BCG-osis, and 
paradoxically elevated lymphocytes. Laboratory testing confirmed hypogammaglob-
ulinemia with normal CD19, but failed to confirm a definitive diagnosis for targeted 
treatment decisions. NIKVal345Met is predicted to be deleterious and pathogenic by two 
in silico prediction tools and is situated in a gene crucial for effective functioning of 
the non-canonical nuclear factor-kappa B signaling pathway. Functional analysis of 
NIKVal345Met- versus NIKWT-transfected human embryonic kidney-293T cells showed that 
this mutation significantly affects the kinase activity of NIK leading to decreased levels 
of phosphorylated IkappaB kinase-alpha (IKKα), the target of NIK. BCG-stimulated 
RAW264.7 cells transfected with NIKVal345Met  also presented with reduced levels of 
phosphorylated IKKα, significantly increased p100 levels and significantly decreased 
p52 levels compared to cells transfected with NIKWT. Ideally, these experiments would 
have been conducted in patient-derived immune cells, but we were unable to source 
these cells from the patient. The functional analysis described in this paper supports 
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previous illustrations of the importance of NIK in human immune responses and 
demonstrates the involvement of function-altering mutations in MAP3K14 in PIDs. 
The genomic approach used for this patient demonstrates its value in the diagnosis 
of an unusual PID and as a tool for detecting rarer mutations to help guide treatment 
approaches.
Keywords: nuclear factor-kappa B-inducing kinase, primary immunodeficiency, tuberculosis, whole exome 
sequencing, Bcg dissemination
inTrODUcTiOn
Primary immunodeficiency disorders (PIDs) are heritable 
genetic errors of the immune system that, if left undiagnosed 
and untreated, may lead to serious, chronic, and in some cases 
fatal infections and manifestations of autoimmunity (1, 2). PIDs 
provide in vivo models for identifying factors crucial for human 
host defense and immune regulation. The nuclear factor-kappa 
B (NF-κB) family of transcription factors found in mammals is 
crucial for the expression of developmental, inflammatory, as 
well as survival genes (3). This pathway consists of a canonical as 
well as a non-canonical arm, with the former involved in expres-
sion of pro-inflammatory genes, and the latter responsible for 
persistent, slower responses generally not associated with innate 
immune responses (4, 5).
The non-canonical NF-κB signaling pathway uses NF-κB-
inducing kinase (NIK), encoded by mitogen-activated protein 
kinase (MAP3K14), to integrate signals from various membrane 
receptors, such as tumor necrosis factor alpha receptor family 
members (6). Several ligands can activate this pathway, includ-
ing B  cell-activating factor, CD40 ligand (CD40L), lympho-
toxin beta, receptor activator of NF-κB ligand (RANKL), and 
TNF-like weak inducer of apoptosis (TWEAK) (7). Binding of 
these ligands to their appropriate receptors cause NIK to phos-
phorylate IkappaB kinase-alpha (IKKα), which activates and 
targets IKKα to p100, its substrate. p100 is in turn phosphoryl-
ated by IKKα, which prompts the ubiquitination and partial 
degradation of p100 to first produce p52 and second permit 
the formation of RelB-p52 complexes. These heterodimeric 
complexes move to the nucleus to activate target genes (3). This 
non-canonical NF-κB pathway controls lymphoid organogen-
esis, activation of dendritic cells and B cell maturation and sur-
vival, and errors in this pathway are associated with lymphoid 
disorders (5).
Although mortality rates due to Mycobacterium tuberculosis 
infections are increased in mice with genetically disrupted 
NF-κB, the role NF-κB plays in human immune responses to 
M. tuberculosis is not well understood (8). It has been speculated 
that some bacterial pathogens misuse specific NF-κB-mediated 
pathways to promote their survival (9). Activation of autophagy 
and apoptosis are two processes through which inhibition 
of NF-κB decreases the amount of intracellular bacilli after 
M. tuberculosis infection (10, 11). Autophagy is associated with 
innate and adaptive immune responses, as well as inflammation 
regulation (12). Ineffective autophagy has been implicated in 
several human diseases, including infectious diseases and inflam-
matory disorders (13–16). IkappaB kinase (IKK), the regulator 
of the NF-κB pathway, is required for autophagy activation in 
mammals, and inhibition of NF-κB increases autophagosome 
formation (17). Classic NF-κB is not involved in this response, 
and the mechanism by which IKK promotes stimulus-induced 
autophagy is largely unknown (18). NIK as well as IKKα are 
degraded by autophagy when the function of heat shock protein 
90, required for the folding and maturation of certain signaling 
proteins, is inhibited (19). The processing of p100 and NF-κB 
activity is thus inhibited (20). However, when heat shock stress 
activates NF-κB, the autophagy pathway is in turn activated, 
indicating a close interaction and tight regulation between these 
two pathways (21).
This study identifies a novel potentially disease-causing 
variant in NIK in a South African PID patient using whole exome 
sequencing (WES). In silico analysis predicts the homozygous 
variant NIKVal345Met to be deleterious and pathogenic. Functional 
studies with human embryonic kidney (HEK)-293T  cells and 
RAW264.7 cells transfected with either NIKWT or NIKVal345Met 
showed that this mutation significantly affects the kinase activity 
of NIK, as well as p100 and p52 levels. The relationship between 
the non-canonical NF-κB signaling pathway and autophagy was 
also investigated in an attempt to shed some light on their poorly 
understood interaction. However, NIKVal345Met did not affect the 
autophagy pathway.
MaTerials anD MeThODs
case report
The proband is a white South African female, from a non- 
consanguineous marriage, initially diagnosed with humoral immu-
nodeficiency after presenting with a Bacillus Calmette-Guérin 
(BCG) abscess on the upper leg at the age of 2 years. She received 
intravenous immunoglobulin (IVIG) replacement therapy. 
A year later she developed BCG meningitis and received standard 
treatment in the acute phase with isoniazid (INH), rifampicin 
(RIF), ethionamide (ETA), and dexamethasone, and thereafter 
only INH and RIF. At the age of 4  years, diffuse granulomas 
were identified in her brain. INH, RIF, ETA, and levofloxacin 
were prescribed for a year, after which the levofloxacin was 
discontinued. In 2014, at the age of 6 years, she presented with 
acute loss of consciousness and raised intracranial pressure. 
Mycobacterium bovis BCG genotypically sensitive to INH and 
RIF was subsequently cultured from the patient. She was started 
on a very aggressive 18-month treatment regimen of levofloxacin, 
terizidone, amikacin IV, linezolid, RIF, INH, para-aminosalisylic 
acid, as well as continued IVIG replacement therapy. With 
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continued dissemination of BCG in spite of the above treatment 
and in the absence of a confirmed PID diagnostic category, the 
patient was not selected for bone marrow transplantation. She 
proceeded to develop severe neurological, motor, as well as cogni-
tive impairment and is now in total dependency care 6 years after 
initial presentation.
Wes analysis
The study was approved by the Health Research Ethics Committee 
of Stellenbosch University (approval no. N13/05/075). Written 
informed consent was granted by the parents of the patient, 
and this included genetic evaluation of the patient. The parents 
also consented to the publication of any molecular findings. 
The study adhered to the ethical guidelines as set out in the 
“Declaration of Helsinki, 2013” (22). Venous blood for DNA 
extraction and WES was drawn from the patient and both of 
her parents. DNA was purified from blood using the Nucleon 
BACC3 Kit (Amersham Biosciences, Buckinghamshire, UK).
Enrichment and sequencing of the exomes of the proband 
and both of her healthy parents were performed with Illumina’s 
TruSeq Exome Enrichment Kit. It targets >20,000 genes with 
>200,000 exons as well as 9 Mb of predicted microRNA targets 
with a total size of 62 Mb. Paired-end WES of the three samples 
was carried out on the Illumina HiSeq 2000, yielding an average 
of 120 million reads per sample and resulting in an average cov-
erage of the target regions of 60–80× after duplicate removal. The 
resulting FASTQ file containing the sequencing data underwent 
quality control in FastQC and was mapped against the human 
reference genome hg38 using Burrows-Wheeler Aligner (BWA). 
PCR duplicates were removed using Picard, while SamTools 
and Genome Analysis Toolkit (GATK) were used in parallel for 
the detection of single-nucleotide variants (SNVs). The variant 
calls from both callers were pooled into a single set, after which 
ANNOVAR was used for SNV annotation and filtering, and to 
interrogate a number of programs and databases for each called 
position to generate more evidence of deleterious mutations. 
The basic filtering options in ANNOVAR used are (1) filtering 
out common SNVs unlikely to be disease-causing based on a 
frequency threshold of >1% in the 1000 Genomes Project 
(1000GP) data (23) and the Exome Sequencing Project 6500 
(ESP6500) data (24); (2) restricting the SNVs to those causing 
amino acid changes in the protein; (3) assessing the impact on 
protein structure through prediction tools; and (4) the presence 
of a gene or SNV in Online Mendelian Inheritance in Man 
(OMIM) or Human Gene Mutation Database (HGMD), which 
shows known disease associations. All variants with negative 
Genomic Evolutionary Rate Profiling (GERP)+++ scores as well 
as all variants with Functional Analysis through Hidden Markov 
Models (FATHMM) scores greater than 0.1 were also removed. 
GERP estimates evolutionary constraints at specific positions in 
an exome and identifies “constrained elements,” where several 
positions combine to produce a signal indicative of a putative 
functional element (25). FATHMM is a high-throughput web-
server that can predict the functional consequences of coding 
and non-coding variants (26). Finally, variants were also removed 
if they were homozygous in either of the healthy parents of the 
proband.
Frequency investigation
The 1000GP data, ESP6500, and ExAC Browser were investigated 
for the presence of all potentially disease-causing variants. Only 
those present in less than 1% of the population in these databases 
were considered as candidate variants.
In Silico Prediction
Project HOPE [Have (y)Our Protein Explained] (27), PolyPhen-2 
(28), Sorting Tolerant From Intolerant (SIFT) (29), and 
MutationTaster2 (30) were used to predict the functional and 
structural causes of the amino acid changes on proteins.
Variant Verification
Sanger sequencing was used to validate the WES results and 
verify whether the potentially disease-causing variants identified 
were true variants or sequencing artifacts. Only one potentially 
disease-causing variant was identified, for which the forward 
and reverse primers F: 5′AGCCCTGGAAACCTCACC and R: 
5′TGAGATTGGCGGAATAAGAGA were used to produce a 
fragment of 455 bp. This was bi-directionally sequenced at the 
Central Analytical Facility of Stellenbosch University using the 
BigDye® Terminator v3.1 Cycle Sequencing kit (Perkin-Elmer, 
Applied Biosystems Inc., Foster City, CA, USA), followed by elec-
trophoresis on an ABI 3130XL Genetic Analyzer (Perkin-Elmer, 
Applied Biosystems Inc., Foster City, CA, USA).
In Vitro Functional analysis
Two plasmids, pWZL-Neo-Myr-Flag-MAP3K14 and pCR-Flag-
IKKalpha, were obtained from the non-profit plasmid reposi tory 
Addgene (https://www.addgene.org/). pWZL-Neo-Myr-Flag-
MAP3K14 was a gift from William Hahn & Jean Zhao (Addgene plas-
mid # 20640) (31) and pCR-Flag-IKKalpha was a gift from Hiroyasu 
Nakano (Addgene plasmid # 15467) (32). To generate the pWZL-
Neo-Myr-Flag-MAP3K14Val345Met mutant construct, the mutation-
specific oligo nucleotide primers F: 5′AAGGCAGCGTGAGCTC 
and R: 5′CAGAGCATGCACTAGGTAT were used together with 
the Q5® Site Directed Mutagenesis Kit (New England Biolabs 
Inc., UK) as per the manufacturer’s instructions. Sanger sequenc-
ing was used to confirm successful mutagenesis.
cell culture and Transfection
Human embryonic kidney-293T cells and RAW264.7 cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 4.5 g/L glucose with l-glutamine and supplemented 
with 10% FBS and 1% penicillin/streptomycin. One day before 
transfection, the cells were trypsinized and seeded into six-well 
culture plates so that the cells were 50–80% confluent the fol-
lowing day. Plasmid DNA was purified from the IKKα as well 
as the wild-type and mutant MAP3K14 plasmids using the 
PureYield™ Plasmid Miniprep System (Promega Corp., USA) 
according to the manufacturer’s guidelines. The IKKα plasmid 
DNA combined with either the wild-type or mutant MAP3K14 
plasmid DNA were then transfected into the seeded HEK293T, 
while only the wild-type or mutant MAP3K14 plasmids were 
transfected into RAW264.7 cells using Lipofectamine™ LTX 
TaBle 1 | Normal cell counts versus patient total cell counts at different ages.
cell counts of the patient at different ages reference
Subsets 2 years, 1 month 2 years, 3 months 4 years, 8 months 5 years, 1 months 6 years 2–6 years
Lymphocytes 15,774 (H) 9,522 (H) 6,720 (H) 3,999 2,366 2,340–5,028
T cells 10,719 (H) 6,785 (H) 4,682 (H) 2,655 1,886 1,578–3,707
CD4+ 8,743 (H) 5,523 (H) 3,954 (H) 2,258 (H) 1,516 870–2,144
CD8+ 1,584 (H) 959 813 533 369 (L) 472–1,107
NK cells 2,549 (H) 1,263 (H) 214 778 (H) 70 (L) 155–565
B cells 2,156 (H) 1,339 (H) 1,783 (H) 398 (L) 362 (L) 434–1,274
Values are given in cells per microliter.
CD, cluster of differentiation; H, high counts; L, low counts; NK, natural killer.
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Reagent and PLUS™ Reagent (Invitrogen, USA) according to 
the manufacturer’s instructions.
Bcg Treatment of cells
The RAW264.7 cells were divided into stimulated and unstimu-
lated groups, each group consisting of untransfected, NIKVal345Met-
transfected, and NIKWT-transfected sub-groups. After transfection 
of the appropriate plasmids into each sub-group, BCG was added 
to each well in the six-well plates making up the stimulated 
group, at a multiplicity of infection of 5. A stock solution BCG 
with a concentration of 1.46 × 106 CFUs/mL was prepared using 
BCG Vaccine SSI (Statens Serum Institut, Denmark) and Diluted 
Sauton SSI (Statens Serum Institut, Denmark). Per well contain-
ing 1 × 106 cells growing in 6 mL growing media, 34 µL of this 
BCG stock solution was added. Cells were stimulated for 16 h 
at 37°C.
Bafilomycin Treatment of cells
The transfected HEK293T  cells used for investigation of 
autophagy were divided into two groups. One received Bafilomycin 
A1 (Baf) treatment while the other remained untreated. Baf is 
a known inhibitor of the late phase of autophagy and prevents 
maturation of autophagic vacuoles by inhibiting fusion between 
autophagosomes and lysosomes (33). A Baf stock solution with a 
concentration of 1 mM was made using DMSO and Bafilomycin 
A1, which was further diluted to 1 µM by adding PBS. Each well 
in one six-well plate seeded with HEK293T cells received 150 µL 
of the 1 µM Baf stock and 1,350 µL growth media, and constituted 
the Baf treatment group. Another plate received only 1,500 µL 
growth media and constituted the control group. The plates were 
incubated for 16 h at 37°C.
cell lysis and Western Blotting
All cells were lysed with lysis buffer [0.05 M Hepes, 0.1 M NaCl, 
0.01  M EDTA, 0.17  mM Triton X-100, 4  mM Nappi, 2  mM 
Na3VO4, and protease inhibitors (Roche)] at 95°C for 5 min and 
all lysates were stored at −80°C. The lysates were subjected to 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS/
PAGE on Mini-PROTEAN® TGX™ precast polyacrylamide 
gels [Bio-Rad Laboratories (Pty) Ltd., RSA] containing 1% SDS, 
after which the proteins were transferred to 0.2-μm-pore poly-
vinylidine difluoride membranes using the iBlot® Dry Blotting 
system (Invitrogen, RSA). Membranes were blocked in 5% BSA 
(w/v) or 5% low fat milk and subsequently probed with the rabbit 
antibodies phospho-IKKα/β (Ser176/180) (16A6), IKKα, NF-κB 
p100/p52, NIK (Cell Signaling Technology, Inc., USA; Abcam 
Inc., UK) and LC3B (Abcam Inc., UK), as well as mouse GAPDH 
antibody (Santa Cruz Biotechnology Inc., USA). Membranes were 
then exposed to horseradish peroxidase-conjugated goat anti-
rabbit and donkey anti-mouse secondary antibodies (Santa Cruz 
Biotechnology, Inc., USA) and the proteins were subsequently 
visualized by enhanced chemiluminescence using Clarity™ 
Western ECL Substrate (Bio-Rad Laboratories, Inc., USA).
statistics
The open platform image analysis tool ImageJ was used for analysis 
of all western blots. All experiments were done in true biological 
triplicates and under the same conditions. One-tailed unpaired 
t-tests were used to determine significant differences between 
samples. All western blots were normalized using GAPDH.
resUlTs
The patient tested negative for the human immunodeficiency 
virus as well as Herpes simplex virus and presented with severe 
hypogammaglobulinemia with decreased immunoglobulin 
(Ig) levels (IgA < 0.06 G/L, IgM = 0.14 G/L, IgG = 0.42 G/L), 
increased lymphocyte subset numbers for her age and normal 
lymphocyte proliferation to mitogens and recall antigens. She 
was investigated for Mendelian susceptibility to mycobacterial 
disease (MSMD) by screening STAT1, LRBA, IL12RB1, IL12B, 
and IFNGR1 for possible disease-causing mutations. No muta-
tions were found in any of these genes. Longitudinal immuno-
logical investigation of this patient with persistent, disseminated, 
treatment-resistant M. bovis BCG infection indicated a dramatic 
decrease of natural killer (NK) cells, B cells, and CD8 cells over 
time (Table 1). Her CD27+IgD+ cell population was decreased 
(2.96%) and class-switched memory B-cells (CD27+IgD−) were 
also low (0.12%), while CD40 ligand (CD40L) was detected as 
present. Memory T  cells were low in relation to naïve T  cells 
and reduced levels of γ/δ T cells were observed—cells known 
to be involved in the innate immune reaction against myco-
bacteria. The patient’s phytohemagglutinin control lymphocyte 
proliferation was normal on the T Spot TB test with negative 
proliferation to specific TB antigens. This is what would be 
expected, since the test is specific for TB antigens, not BCG—
the cause of disease dissemination observed in this patient. 
Upregulation of CD69 on NK cells after interleukin-2 stimulation 
TaBle 2 | Variants identified by WES in the proband and both parents.
Father Mother Patient
Total variants 23,440 23,474 23,939
All synonymous and non-frameshifts removed 11,707 11,693 11,925
Remove all variants with a frequency >1% 
in 1KGP
2,357 2,377 2,495
Remove all variants with a frequency >1%  
in ESP6500
2,077 2,107 2,160
Remove all variants with negative GERP+++ 
scores
1,514 1,481 1,535
Remove all variants with positive FATHMM 
scores
703 688 708
Novel variants 108 113 114
Variants with rs numbers 595 575 594
ESP6500, Exome Sequencing Project 6500; GERP, Genomic Evolutionary Rate 
Profiling; FATHMM, Functional Analysis through Hidden Markov Models; WES, whole 
exome sequencing; 1KGP, 1000 Genome Project.
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was slightly decreased. T cell receptor excision circles (TRECs) 
and kappa-deleting recombination excision circles were clearly 
visible (AMPATH Laboratories, South Africa). Investigation by 
WES was thus pursued to assist with establishing a diagnosis 
for this patient.
identification of a homozygous  
Mutation in niK
Whole exome sequencing of the proband revealed a total of 
23,939 variants, which were reduced to 708 candidate variants 
after filtering and annotation using ANNOVAR (Table 2). Upon 
exclusion of all variants present in a homozygous state in either 
of the healthy parents, 9 homozygous and 23 heterozygous 
variants remained (Table  3). After interrogating OMIM and 
HGMD, only one variant was identified as potentially disease-
causing according to the function of the gene it is situated in. 
This homozygous c.G1033A p.Val345Met nucleotide variant 
is situated in exon 5 of NIK (Table  4). SIFT and PolyPhen-2 
predicted this change to be pathogenic and damaging, while 
MutationTaster2 was not able to generate any results, indicating 
the uncharacterized state of NIK. The variant is situated at a 
position that is highly conserved across several different species 
(Figure 1).
This variant was covered 65× during WES, improving its 
likelihood of being a true variant rather than a sequencing 
artifact. The average coverage for all the variants identified in 
the proband was 105×. Sanger sequencing confirmed this to be 
a true variant present in a homozygous state in the patient and 
heterozygous in both unaffected parents (Figure 2). NIKVal345Met 
was absent from all interrogated databases and therefore 
previously unidentified in all investigated populations. No mis-
sense or loss-of-function mutations in NIK are listed in these 
databases.
In Silico Variant Prediction
A schematic representation of the amino acid exchange caused by 
this variant, with wild-type valine (Val) on the left and mutated 
methionine (Met) on the right, is shown in Figure 3A. Met and 
Val are both non-polar, hydrophobic, and aliphatic amino acids. 
Figure 3B shows the difference in size between Val and Met. The 
main difference is the presence of a C-beta branch in Val: two 
non-hydrogen substituents attached to its C-beta carbon, instead 
of only one as for Met. Met also has an additional sulfur atom, 
which forms very strong amide N–H⋅S hydrogen bonds crucial 
for controlling the conformational setting of this amino acid (35). 
Val is bulkier near the protein backbone and more restricted in 
the conformations the main-chain can adopt. The Val side chain 
is extremely non-reactive and is rarely directly involved in protein 
function, although it can play a role in substrate recognition. The 
site of variation is situated near a conserved site.
The HOPE analysis indicated that Val345Met is located 45 
amino acid positions before the interpro domain known as 
mitogen-activated protein kinase kinase kinase 14 (IPR017425), 
associated with protein kinase and transferase activity. This 
kinase domain stretches from positions 390 to 660 (Figure 4). 
Because of its close proximity to the kinase domain, it is tempt-
ing to speculate that Val345Met may have an effect on the ability 
of NIK to phosphorylate IKKα. This domain is in contact with 
residues from other domains, implying the possibility for the 
variant to influence correct protein function by inhibiting/alter-
ing these interactions.
Plasmid Transfection into human cells
To experimentally assess the effect of the mutation of interest, 
we analyzed the kinase activity of NIKVal345Met compared to NIKWT 
by testing NIK-dependent phosphorylation of IKKα. Sanger 
sequencing first confirmed that the mutagenesis occurred 
correctly (Figure S1 in Supplementary Material). IKKα in com-
bination with either wild-type or mutant NIK were transfected 
into HEK293T cells, while only NIK, in either its wild-type or 
mutant form, was transfected into RAW264.7 cells. The NIK and 
IKKα antibodies were then used to show that transfection of the 
plasmids expressing IKKα and mutant and wild-type NIK into 
HEK293T and RAW264.7 cells was successful. Untransfected 
HEK293T cells do not contain endogenous NIK, although they do 
contain IKKα, while RAW264.7 cells contain both NIK and IKKα 
endogenously. As seen in Figure S2 in Supplementary Material, 
there was an increase of both the expression of IKKα in both wild-
type and mutant NIK cotransfected HEK 293T  cells (although 
this increase did not reach statistical significance; p =  0.0638). 
Similarly, there was an increase in NIK levels in RAW264.7 cells 
following transfection with wild-type and mutant NIK constructs 
(Figure S3 in Supplementary Material). No significant differences 
are observed between the transfection efficiencies of wild- 
type- and mutant-transfected cells in either of these cell types.
Phosphorylation assay
IkappaB kinase-alpha and phospho-IKKα/β (Ser176/180) 
antibodies were used to investigate the difference between IKKα 
and phospho-IKKα levels in NIKWT compared to NIKVal345Met. 
NIKVal345Met was not thought to affect the production of IKKα 
and as expected, the level of IKKα was not substantially altered 
by this mutation (Figure  5A: p  =  0.3879; Figures  6A,C,E; 
unstimulated: p  =  0.4757; stimulated: p  =  0.1844). However, 
TaBle 4 | Details of the putative disease-causing variant identified in the 
proband.
Chromosome 17
Position 45286550
Gene name MAP3K14/NIK
Refseq NM_003954.4
Reference sequence G
PROBAND: number of reads with reference 0
FATHER: number of reads with reference 22
MOTHER: number of reads with reference 17
Alternative sequence A
PROBAND: number of reads with alternative 65
FATHER: number of reads with alternative 26
MOTHER: number of reads with alternative 20
Mutation type Nonsynonymous SNV
Mutation: DNA (HGVS nomenclature_c.) c.G1033A
Mutation: protein (HGVS nomenclature_p.) p.VAL345MET (NP_003945.2)
Prediction < SIFT Damaging
Prediction < PolyPhen-2 Probably damaging
Prediction < MutationTaster2 N/A
Sanger verification Yes
NIK, NF-κB-inducing kinase; SNV, single-nucleotide variant; SIFT, Sorting Tolerant From 
Intolerant; HGVS, Human Genome Variation Society; N/A, not applicable.
TaBle 3 | Final list of variants identified in the proband after filtering.
gene Variant exac dbsnP caDD_phred scores
homozygous variants
CELA1 c.6_7insC; p.V3fs 0.383 – –
FOXD4 c.748_749del:p.G250fs 0.189 – –
FOXD4 c.753_754insCG:p.G252fs 0.189 – –
GJD3 c.C523T:p.H175Y 0.00401 rs202055764 13.57
GJD3 c.G758C:p.R253P 0.00286 rs532965992 –
LRRC46 c.10_11insGT:p.G4fs 0.000602 rs536101939 –
MAP3K14 c.G1033A:p.V345M – – 18.77
NBPF1 Unknown 0.52 rs2990550 –
SYN2 Unknown 0.000729 – –
heterozygous variants
C2CD4C c.C205A:p.L69M 0.00134 rs200204713 10.36
CASP5 c.67delA:p.R23fs – rs372526393 –
CCDC150 c.839delA:p.Q280fs – rs376590781 –
CD36 c.G1016T:p.G339V 0.000602 rs146027667 21.3
CDC27 c.C1697T:p.A566V – – 36
CEP164 c.337delA:p.K113fs – – –
CES1 c.A145G:p.I49V 0.303 rs3826193 10.91
CES1 c.G53T:p.G18V 0.285 rs3826190 18.35
CXorf40B c.T159G:p.C53W 0.00747 rs140921811 1,305
FBXW10 c.T2552C:p.V851A 0.000155 rs199779085 9,638
FOXD4L1 c.A463G:p.I155V 0.000705 rs199845792 18.09
KRT18 c.C300G:p.S100R – – 16.24
KRT18 c.C308A:p.T103N – – 14.54
KRT18 c.C316T:p.R106W – rs11551638 14.74
MTCH2 c.G196A:p.G66R – – 27.9
OPALIN c.G52T:p.A18S 0.00449 rs35821065 25.2
PAK2 c.A383G:p.K128R 0.028 rs78043821 21.6
PLEC c.G8992A:p.E2998K 0.000982 rs200898220 7,527
RASA4, RASA4B c.A1054G:p.M352V 0.124 rs144395384 7.05
SERPINA4 c.C403T:p.R135C 0.0000244 – 15.31
SLC11A2 c.C1291A:p.L431I 0.00251 rs144863268 19.37
SPDYE6 c.C890T:p.P297L 0.00348 rs202078839 –
UBXN11 c.1104_1181del:p.368_394del 0.301 – –
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stimulated: p < 0.0001) cells, indicating that this mutation alters 
the kinase activity of NIK. The ratio of phosphorylated IKKα to 
un-phosphoryla ted IKKα is shown in Figure 6G, with a significant 
difference observed between the wild-type-transfected and the 
mutant-transfected cell groups that have been stimulated with BCG 
(p = 0.0090).
Downstream Functional effects  
of niKVal345Met
Phosphorylated IKKα results in the ubiquitination and pro-
teosomal degradation of p100 to produce p52. The difference 
in p100 and p52 levels between cells expressing wild-type and 
mutant NIK was thus also investigated to determine whether 
NIKVal345Met has any downstream effects. The ideal would have 
been to use patient-derived immune cells for these experi-
ments to more accurately measure the downstream effects of 
the identified mutation. Unfortunately, the patient deteriorated 
to such an extent that we could not obtain more blood samples 
from her. HEK293T  cells, that are incapable of eliciting an 
immune response upon infection, were first used. However, 
no quantifiable levels of p52 were detected (Figure 5B), while 
no significant differences in the levels of p100 were observed 
between wild-type- and mutant-transfected groups (Figure 5B; 
p  =  0.7409). p100 and p52 levels were also measured in 
phosphorylated IKKα levels were significantly reduced by 
NIKVal345Met in both HEK293T (Figure  5A; p  =  0.0353) and 
RAW264.7 (Figures  6B,D,F; unstimulated: p  =  0.0010; 
FigUre 1 | ClustalW multiple sequence alignment. The c.G1033A (p.Val345Met) homozygous mutation identified in this patient is situated at a highly conserved 
position in MAP3K14 (34).
FigUre 2 | Validation by Sanger sequencing of NIKVal345Met found by whole exome sequencing. Patient’s c.G1033A homozygous mutation, with one mutated allele 
inherited from each of the healthy, heterozygous parents.
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BCG-stimulated and unstimulated RAW264.7 cells transfected 
with NIKVal345Met and NIKWT. In BCG-stimulated cells, p100 
levels were significantly increased (p = 0.0458) and p52 levels 
decreased (p =  0.0208) in the mutant compared to the wild-
type groups (Figures  6C,H,I). The difference in p100 levels 
between the mutant and wild-type groups was not significant in 
BCG-unstimulated RAW264.7 cells (Figures 6B,I; p = 0.1745), 
although the decrease in p52 levels remained significant in the 
unstimulated cells (Figures 6B,H; p = 0.0330). The NIKVal345Met 
variant thus significantly affects the downstream functioning 
of the non-canonical NF-κB signaling pathway. The ratio of 
p52 to p100 is shown in Figure 6J, with significant differences 
observed between the wild-type-transfected and the mutant-
transfected cell groups in both BCG-stimulated and unstimu-
lated cell populations (unstimulated: p =  0.0077; stimulated: 
p = 0.0053).
effect of niKVal345Met on autophagy
Autophagy is a dynamic catabolic process during which double-
membrane vesicles (autophagosomes) form by engulfing parts of 
the cytoplasm and subsequently fuse with lysosomes to degrade 
and recycle their contents (36). LC3 immunoblotting is widely 
used to measure autophagic activity (37–39). SDS-PAGE and 
immunoblotting detects two bands of endogenous LC3, namely 
LC3-I and LC3-II. LC3-I is present in the cytosol, while LC3-II is 
bound to phosphatidylethanolamine and localized to autophago-
somal membranes (40, 41), thus directly correlating with the 
number of autophagosomes (42). The effect of NIKVal345Met on 
autophagy was also investigated in this study by measuring 
LC3-II levels. The western blots and corresponding bar graphs 
are shown in Figure 5C. Significant differences in LC3-II were 
observed when comparing cells transfected with NIKWT before 
and after Baf treatment (p =  0.0418), as well as those infected 
FigUre 4 | Schematic representation of NIK protein domain structures. The NRD (light blue) contains the BR and the P-RR domains (darker blue). The conserved 
domain containing V345M (purple label) is indicated in pink and situated before the kinase domain (green). This is followed by the NCR (gray). The P565R amino 
acid change observed in P1 and P2 by Willmann et al. is situated in the kinase domain. Black labels indicate the mutations previously observed in the murine studies 
(Lys429Ala; Lys430Ala; Gly860Arg). TRAF3, tumor necrosis factor receptor-associated factor 3; NRD, negative regulatory domain; BR, basic region; P-RR, 
proline-rich repeat; NCR, non-catalytic region; Lys, lysine; Ala, alanine; Pro, proline; Arg, arginine; Gly, glycine; Val, valine; Met, methionine; IKKα, IkappaB 
kinase-alpha; NIK, NF-κB inducing kinase (44).
FigUre 3 | Amino acid changes caused by the mutation identified in the proband. (a) Mutation of Val to Met, as observed at position 345 in NIK of the patient.  
The conserved backbone is indicated in red, with the unique side-chain in black. (B) Mutant Met (red) is larger than wild-type Val (green), potentially influencing 
interactions within the protein as well as with other proteins (27).
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with NIKVal345Met before and after treatment (p =  0.0366), thus 
indicating effective functioning of the autophagic pathway. When 
comparing the difference in LC3-II levels between mutant and 
wild-type groups (Figure 5C), however, no significant difference 
was observed (p =  0.9506), indicating that NIKVal345Met has no 
effect on autophagy.
DiscUssiOn
Phenotype heterogeneity is often observed in patients with 
mutations in the same gene, and this may in part depend on 
the patient’s environment (43). We identified a patient with a 
mutation in NIK where the phenotype was modified by early 
BCG exposure as part of routine vaccination in the first days 
of life.
Only one previous study to date has described mutations in 
NIK in humans and identified a bi-allelic mutation as the cause 
of a primary immunodeficiency characterized by multifaceted 
aberrant lymphoid immunity in two patients (44). Patient 1 (P1) 
was born to consanguineous healthy parents and had a younger 
brother who died at the age of 2 years from suspected combined 
immunodeficiency. Decreased IgG and IgA and elevated IgM 
levels were identified on a single occasion before any treatment 
was prescribed. Despite treatment (such as regular intravenous 
Ig substitution and ganciclovir), the patient continued to suffer 
from multiple episodes of bacterial and viral infections. There 
was also one documented episode of granulomatous hepatitis and 
tuberculosis osteomyelitis due to dissemination after BCG vac-
cination. An allogeneic hematopoietic stem cell transplantation 
(HSCT) after reduced toxicity conditioning was performed at the 
FigUre 5 | Continued
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age of 9 years, and upon last report in 2014 she remained clini-
cally well. Patient 2 (P2) is a first-degree cousin of P1 also born 
to consanguineous healthy parents. She presented with severe 
chronic diarrhea, recurrent lower respiratory tract infections, 
as well as oral and esophageal candidiasis. She tested positive 
for Cryptosporidium on one occasion. Her human leukocyte 
antigen-identical mother was used as a donor for an allogeneic 
HSCT performed without conditioning at the age of 3  years. 
As no engraftment was observed after 50 days, the same donor 
was used and a second transplant was performed. However, the 
patient died on day 6 following the second HSCT due to rapidly 
accelerated septic shock and multi-organ failure.
We describe a patient with similar symptoms: initial diagnosis 
of humoral immunodeficiency with severe hypogammaglobu-
linemia, decreased memory B cells, B cell lymphopenia, normal 
T  cell proliferation to mitogens and recall antigens, as well as 
normal IFN-γ production by T cells (Table 1). However, while 
the patients from the previous study presented with recurrent 
FigUre 5 | Comparison between NIKVal345Met- and NIKWT-transfected HEK293T cells. (a) No phospho-IKKα was detected in untransfected HEK293T cells, with 
significant amounts present in transfected cells, proving efficient transfection. A significant decrease in phospho-IKKα is observed in cells transfected with NIKVal345Met 
compared to NIKWT. The ratio of phospho-IKKα over IKKα is also significantly affected by NIKVal345Met. a: p = 0.0084*; b: p = 0.3879; c: p = 0.0003*; d: p = 0.0353*; 
e: p = 0.0199*. (B) No quantifiable p52 levels were observed in untransfected, wild-type-transfected, or mutant-transfected samples. p100 was detectable at 
significant amounts, but no differences between the wild-type and mutant groups were observed. a: p = 0.7409. (c) Significant differences were seen when 
comparing cells transfected with wild-type NIK and IKKα before and after Baf treatment, as well as mutant NIK and IKKα before and after treatment. However, the 
difference in autophagy between wild-type-transfected and mutant-transfected groups was not significant. a: p = 0.0418*; b: p = 0.0366*; c: p = 0.9506. Each 
image is representative of three experiments conducted independently. * indicates significance.
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viral, bacterial, and Cryptosporidium infections, the phenotype 
of our patient seems to be confined to BCG-osis. Our patient 
did not present with any other infections. WES and subsequent 
bioinformatics analysis identified a novel putative disease-causing 
homozygous variant, c.G1033A, situated in NIK. NIK encodes the 
947 residue protein mitogen-activated protein kinase 14, which 
FigUre 6 | Continued
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is a serine/threonine protein kinase involved in NF-κB activity 
(NM_003954.4). The NIKVal345Met variant identified in this patient 
has never been described and is predicted to be disease-causing 
and deleterious by two in  silico prediction tools. It is difficult 
to predict the exact result of this variant on protein function, 
since NIK is poorly characterized. The variant is situated in a 
12
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FigUre 6 | Continued
FigUre 6 | Comparison between NIKVal345Met- and NIKWT-transfected RAW264.7 cells. (a,B) Similar amounts of IKKα was detected in the wild-type and mutant 
cell groups, indicating that NIKVal345Met had no effect on IKKα production. p100 levels were similar in the wild-type and mutant RAW264.7 cell line groups, with 
reduced levels of phospho-IKKα and p52 observed in cells transfected with NIKVal345Met compared to NIKWT, without BCG stimulation. (c,D) p100, p52, and 
phospho-IKKα levels were affected by the Val345Met mutation, with increased p100, and decreased p52 and phospho-IKKα levels observed in BCG-stimulated 
cells transfected with NIKVal345Met compared to NIKWT. IKKα levels were not affected. (e) Quantification of western blots in (a,c) showed similar amounts of IKKα  
in wild-type and mutant cell groups, both without and with BCG stimulation. a: p = 0.4757; b: p = 0.1844; (F) quantification of western blots in (B,D) show 
significant reductions in phospho-IKKα in the mutant-transfected cell groups compared to the wild-type-transfected groups, both without and with BCG 
stimulation. a: p = 0.0010*; b: p < 0.0001*. (g) The ratio of phosphorylated IKKα over un-phosphorylated IKKα was similar between the wild-type- and 
mutant-transfected cell groups in the absence of BCG stimulation, but significantly reduced in the mutant-transfected groups compared to the wild-type-
transfected groups when stimulated with BCG. a: p = 0.0760; b: p = 0.0090*. (h) Significantly reduced levels of p52 was observed in cells transfected with 
NIKVal345Met compared to NIKWT, both in the absence and in the presence of BCG stimulation. a: p = 0.0330*; b: p = 0.0208*. (i) p100 levels were similar in cells 
transfected with NIKVal345Met compared to NIKWT without BCG stimulation. However, p100 levels significantly increased in the NIKVal345Met-transfected groups upon 
BCG stimulation. a: p = 0.1745; b: p = 0.0458*. (J) The ratio of p52 over p100 differed significantly between cells transfected with NIKVal345Met compared to 
NIKWT, both without and with BCG stimulation. a: p = 0.0077*; b: p = 0.0053*. The data for each image in this figure is representative of three experiments 
conducted independently. * indicates significance.
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highly conserved region (Figure 4). The domain it is located in 
is important for NIK’s activity and interacts with residues from 
other domains, making it possible for this mutation to inhibit 
the correct functioning of NIK. The involvement of NIK in B cell 
development and maturation makes it a perfect candidate gene 
to investigate further for association with primary immunodefi-
ciency and increased susceptibility to TB.
Phenotypic heterogeneity may be due to different effects of a 
mutation on protein function (43). However, clinical phenotypic 
variation cannot always be attributed to different functional 
consequences of a mutation. As an example, the first patient 
in whom a mutation in TYK2 (member of the JAK family of 
tyrosine kinases) was identified was diagnosed with hyper-IgE 
syndrome accompanied by lesions of the skin, BCG disease, as 
well as fungal and viral infections (45). A second patient, also 
with small deletions in TYK2 and the absence of protein on west-
ern blots like the first patient, presented with BCG disease and 
brucellosis, but had normal IgE levels and no skin lesions (46). 
In a further example, three Chinese siblings with intracranial 
calcifications and epileptic seizures, without severe infectious 
diseases, were exome sequenced and a mutation in ISG15 was 
identified (47). Mutations in this gene were previously found to 
cause MSMD in three unrelated children from two families in 
Iran and Turkey (48). Subsequently, intracranial calcifications 
were also identified in other ISG15-deficient patients. The 
Chinese individuals never received BCG vaccinations, which 
could explain why they did not have the MSMD phenotype. 
Even within a single family, mutations in the same gene have 
been shown to cause very different clinical phenotypes (35). This 
is due to the range of infectious or environmental exposures, 
age of exposure and various modifying epigenetic factors that 
can affect disease presentation. Therefore, clinical outcomes 
of patients with immunodeficiencies, even with previously 
described phenotype/genotype associations, cannot always be 
accurately predicted.
Phenotypic differences observed between the proband in this 
study and P1 and P2 described by Willmann and colleagues 
can also be attributed to the location, and thus the effect, of the 
identified mutations. The previously identified mutation is situ-
ate in the kinase domain of NIK, and completely abolishes the 
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